HIV Flashcards

1
Q

What type of virus is HIV?

A

Enveloped, diploid, single-stranded, positive-sense RNA viruses with a DNA intermediate (which is an integrated viral genome (a provirus) that persists within the host-cell DNA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does HIV produce cellular immune deficiency?

A
  • Characterized by the depletion of helper T lymphocytes (CD4+ cells)
  • The loss of CD4+ cells results in the development of opportunistic infections and neoplastic processes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

By the #s - global estimates for adults and children, 2008 vs. 2016

A
  • People living with HIV – 33.4 million vs 36.7 million
  • New HIV infections 2.7 million vs 1.8 million
  • Deaths due to AIDS 2.0 million vs 1.0 million
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which age bracket contains the largest % of HIV cases?

A

20-29 y/o make up 37% of HIV cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which modes of transmission have the highest % likelihood?

A
  • Mother-infant 15-35% (*~2%)

- Transfusion 80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Who should get tested for HIV?

A
  • All patients aged 13-64 in all health-care settings*
  • HIV screening should be voluntary
  • Opt-out screening: patients are notified that testing will be performed unless they decline
  • Separate written consent for HIV testing not recommended; general informed consent is sufficient
  • Prevention counseling should not be required
  • High-risk patients should be screened at least annually
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Who is at highest risk for HIV?

A
  • Unprotected sexual intercourse, especially receptive anal intercourse (8-fold higher risk of transmission)
  • A large number of sexual partners
  • **Prior or current sexually transmitted diseases (STDs):
  • Sharing of intravenous drug paraphernalia
  • Receipt of blood products (before 1985 in the United States)
  • Mucosal contact with infected blood or needle-stick injuries
  • Maternal HIV infection (for newborns, infants, and children)
  • Gay and bisexual men (including transgender), particularly young African American, are most affected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which STDs increase risk for HIV?

A

Gonorrhea and chlamydia infections increase the HIV transmission risk 3-fold, syphilis raises the transmission risk 7-fold, and herpes genitalis raises the transmission risk up to 25-fold during an outbreak

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

List the ways to reduce HIV risk

A
  • Consistent, correct condom use
  • Screening and tx of STIs in individuals at risk for HIV
  • Addiction tx for IV drug users and/or participation in needle exchange programs
  • In those with high ongoing risk for infection daily pre-exposure prophylaxis with tenofovir-emtricitabine (Truvada)
  • If mucosal or parenteral exposure to HIV within the prior 72 hours, post exposure prophylaxis with ART
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which patients should have HIV screening at least annually?

A
  • Injection-drug users (IDUs)
  • Sex partners of IDUs
  • Persons who exchange sex for money or drugs
  • Sex partners of HIV infected
  • Men who have sex with men (MSM)
  • Heterosexuals who themselves or their sex partners have had >1 sex partner since last HIV test
  • Before new sexual relationship
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnosis of HIV

-acute or early infection

A

Combination antigen/antibody immunoassay and HIV viral load (RT-PCR based)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnosis of HIV

-immunoassay/VL results

A

(-) immunoassay and (-) VL signifies no HIV infection (if recent exposure repeat in 1-2 weeks)

(-) immunoassay and (+) VL suggests an early infection (VL <1000 copies/ml very rarely represents false positive test, repeat!)

(+) immunoassay and (+) VL, early or established infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the next step in the event of (+) immunoassay?

A

(+) immunoassay needs a second, antibody-only immunoassay (preferably the HIV-1/HIV-2 differentiation immunoassay) if not already performed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the 3 phases of HIV/AIDS?

A
  1. Primary HIV infection
  2. Chronic asymptomatic phase
  3. Advanced AIDS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Etiology of primary HIV infection

A
  • Symptomatic illness in 40-90%
  • Illness is nonspecific and mononucleosis-like
  • Appears 2-4 weeks after exposure
  • Clinical illness lasts 1-4 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

List the acute retroviral syndrome symptoms

A
  • Fever
  • Lymphadenopathy
  • Pharyngitis
  • Rash
  • Myalgias
  • GI complaints
  • Encephalopathy

*Ask your patient if at any point since their last HIV (-) test they’ve experienced these symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the rash seen with primary HIV

A
  • Maculopapular rash affecting face, neck, and trunk
  • Usually individual lesions < 1cm
  • Confluence rare
18
Q

What lab values will you see with primary HIV?

A
  • Thrombocytopenia
  • Leukopenia
  • WBCs drop
  • Elevated ALT, AST
  • Elevated ESR
  • ELISA often negative (window period)
19
Q

Define the chronic asymptomatic phase

A

Characterized by a long phase of clinical latency (median 10 yrs)

20
Q

What is happening with viral replication in chronic asymptomatic phase? Where is the virus replicating?

A
  • Viral replication and CD4+ counts are relatively stable

- Virus is actively replicating in lymphoid tissue causing anatomic and functional deterioration

21
Q

When should we consider our patient to be in category of chronic asymptomatic phase?

A

If our patient has no signs/symptoms of OIs (opportunistic infections) and last HIV test was 7 years ago she might be in this category

22
Q

Etiology of advanced AIDS

A
  • Defines the end stage of HIV infection
  • Leads to death in 2-3 years in the absence of therapy (opportunistic infections)
  • Characterized by high plasma viral load and low CD4+ count
23
Q

List common opportunistic infections

A
  • PCP pneumonia
  • CMV
  • Disseminated/ extrapulmonary MAC
  • Wasting syndrome
  • Invasive cervical cancer
  • Kaposi’s sarcoma
24
Q

What can you tell your patient about her life expectancy?

A
  • HIV is no longer a ‘death sentence’
  • Diabetes mellitus can be a useful analogy
  • Chronic, incurable disease
  • Requires daily medications
25
Q

What lab test will you order?

A
  • CD4 T-cell count
  • HIV RNA/viral load
  • CBC with differential
  • CMP
  • TB
  • Drug resistance

*variety of others, review slide

26
Q

What does CD4 count of 500-1,500 mean?

A

Normal range, usually symptom-free

27
Q

What does CD4 count of < 500 mean?

A

Increased risk for HIV-related minor phenomena, e.g. seborrheic dermatitis, generalized lymphadenopathy, periodontal disease

28
Q

What does CD4 count of < 300-350 mean?

A

Increased risk for recurrent bacterial pneumonia, TB, lymphoma, Kaposi’s sarcoma, oral candidiasis, zoster

29
Q

What does CD4 count of < 200 mean?

A

increased risk for major opportunistic infections: PCP, esophageal candidiasis, chronic mucocutaneous HSV, cryptosporidiosis

30
Q

What prophylaxis can you give with CD4 count < 200?

A

Bactrim DS 1 tab PO daily for PCP prophylaxis

31
Q

What does CD4 count of < 50-100 mean?

A

Profound increased risk for all opportunistic processes

32
Q

What are the new recommendations for starting ART?

A

Initiate ART soon after initial diagnosis in nearly all HIV-infected patients, regardless of the CD4 count

33
Q

What should you consider in patients needing to start ART?

A

Some patients may have barriers to taking daily therapy because of concurrent conditions (e.g., active depression, substance use) or social instability (e.g., homelessness)

34
Q

What CD4 counts go into considerations with patients with barriers?

A
  • CD 4 > 350 cells/microL (especially > 500 cells/micoL) and no HIV-related symptoms or complications we may choose to delay therapy
  • Once CD4 < 350 cells/micoL we initiate ART regardless of these barriers
35
Q

What are the goals of HIV treatment?

A
  • Reduce HIV-related morbidity and mortality
  • Restore and/or preserve immunologic function
  • Maximally and durably suppress HIV viral load
  • Prevent HIV transmission
36
Q

What are potential barriers to adherence to HIV treatment?

A
  • Ongoing substance abuse
  • Pill burden
  • Inconvenient dosing schedule
  • Dietary restrictions
  • Denial
37
Q

List the predictors of poor adherence

A
  • Active alcohol or substance abuse
  • Work outside the home for pay
  • Depressed mood
  • Lack of perceived efficacy of ART
  • Lack of advanced disease
  • Concern over side effects
  • Regimen complexity
38
Q

Health care maintenance - what vaccines should HIV patients have?

A
  • Hepatitis A, hepatitis B (if not immune)
  • Pneumococcal
  • Influenza
  • Tetanus
39
Q

What is the recommendation for pap smears in HIV patients?

A

-Every 6 months initially, then yearly if negative*
**Not less than once per year!!
0If comes back as ASCUS cells or more significant abnormality, get colposcopy per latest guidelines (do not triage by HPV status)

40
Q

Health care maintenance - breast, prostate, colorectal cancer screening

A

Same as for HIV-negative patients

41
Q

Health care maintenance - cholesterol screening

A
  • Protease inhibitors, efavirenz, some NRTIs associated with dyslipidemia
  • Check baseline lipids before treatment and periodically after initiation of treatment
  • Higher rates of CAD among HIV-infected patients
42
Q

What referrals apply to patients in Oklahoma?

A
  • Ryan White Care Act Part B: Grantee is the Oklahoma State Department of Health.
  • Services provided are case management, dental, mental health/substance abuse, transportation, lab, HIV testing and counseling, medicines, & HDAP